We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Benitec Biopharma Limited (BNTC - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Benitec Biopharma Limited is a member of our Medical group, which includes 999 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Benitec Biopharma Limited is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BNTC's full-year earnings has moved 61.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BNTC has returned 7.7% so far this year. In comparison, Medical companies have returned an average of -5.6%. This means that Benitec Biopharma Limited is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Concentra Group (CON - Free Report) . The stock has returned 14.9% year-to-date.
Over the past three months, Concentra Group's consensus EPS estimate for the current year has increased 4.5%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Benitec Biopharma Limited belongs to the Medical - Biomedical and Genetics industry, which includes 506 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have lost 6.5% this year, meaning that BNTC is performing better in terms of year-to-date returns.
On the other hand, Concentra Group belongs to the Medical Services industry. This 58-stock industry is currently ranked #51. The industry has moved -2.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Benitec Biopharma Limited and Concentra Group as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Benitec Biopharma Limited (BNTC - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Benitec Biopharma Limited is a member of our Medical group, which includes 999 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Benitec Biopharma Limited is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BNTC's full-year earnings has moved 61.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BNTC has returned 7.7% so far this year. In comparison, Medical companies have returned an average of -5.6%. This means that Benitec Biopharma Limited is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Concentra Group (CON - Free Report) . The stock has returned 14.9% year-to-date.
Over the past three months, Concentra Group's consensus EPS estimate for the current year has increased 4.5%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Benitec Biopharma Limited belongs to the Medical - Biomedical and Genetics industry, which includes 506 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have lost 6.5% this year, meaning that BNTC is performing better in terms of year-to-date returns.
On the other hand, Concentra Group belongs to the Medical Services industry. This 58-stock industry is currently ranked #51. The industry has moved -2.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Benitec Biopharma Limited and Concentra Group as they could maintain their solid performance.